Long-lasting humoral immunity in Covid-19 infected patients at a University Hospital Clinic in Östergötland County Council during 2020-2021
Preprint
Abstract
Longitudinal serum samples and nasopharyngeal/nasal swab samples were collected from forty-eight individuals (median age 66yrs) with Covid-19 PCR-positive test results at Linköping University Hospital. Samples were collected from initial visit and for 6 months follow up. Presence of serum IgG and IgA against SARS-CoV-2 antigens (S1-spike, nucleocapsid and NSP3) were analyzed. Nasal swabs were tested for presence of IgA against the outer envelope S1 spike protein. Ninety-two percent of participants were seropositive against SARS-CoV-2 recombinant proteins at day 28 from study entry and all (100%) were seropositive from samples collected at 2 months or later. The most common antibody responses (both serum IgG, mainly IgG1 and IgA) were detected against the S1-spike protein and the nucleoprotein. In samples collected from nasal tissues considerably lower frequencies of IgA-positive reactivities were detected. Sixteen to 18 percent of study participants showed detectable IgA levels in nasal samples, except at day 60 when 36% of tested individuals showed presence of IgA against the S1-spike protein. The study suggests that the absolute majority of studied naturally infected Covid-19 patient in the Linkoping, Ostergotland health region develop over 6 months lasting detectable levels of serum IgG and IgA responses towards the SARS-CoV-2 S1-spike protein as well as against the nucleoprotein, but not against the non-structural protein 3.Keywords
This publication has 19 references indexed in Scilit:
- Expansion of SARS-CoV-2–Specific Antibody-Secreting Cells and Generation of Neutralizing Antibodies in Hospitalized COVID-19 PatientsThe Journal of Immunology, 2020
- SARS-CoV-2 exposure, symptoms and seroprevalence in healthcare workers in SwedenNature Communications, 2020
- Potently neutralizing and protective human antibodies against SARS-CoV-2Nature, 2020
- Respiratory Syncytial Virus (RSV) Neutralizing Antibodies at Birth Predict Protection from RSV Illness in Infants in the First 3 Months of LifeClinical Infectious Diseases, 2020
- Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2International Journal of Biological Sciences, 2020
- Current perspectives in assessing humoral immunity after measles vaccinationExpert Review of Vaccines, 2018
- A comparison of hemagglutination inhibition and neutralization assays for characterizing immunity to seasonal influenza AInfluenza and Other Respiratory Viruses, 2016
- Pandemic Influenza A(H1N1)pdm09 Seroprevalence in Sweden before and after the Pandemic and the Vaccination Campaign in 2009PLOS ONE, 2012
- Swedish inactivated polio vaccine: Laboratory standardization and clinical experience over a 30-year periodBiologicals, 1992
- Polio immunity to killed vaccine: an 18-year follow-upVaccine, 1990